Effect of Saffron Extract, Astaxanthin, and Carnosic Acid on the Levels of Matrix Metalloproteinase-9 and on Body Weight Changes in Arthritis Experiments

M. Chrastina, S. Poništ, F. Dráfi, K. Švík, S. Khademnematolahi, K. Pružinská, A. Tchorbanov, K. Bauerová
{"title":"Effect of Saffron Extract, Astaxanthin, and Carnosic Acid on the Levels of Matrix Metalloproteinase-9 and on Body Weight Changes in Arthritis Experiments","authors":"M. Chrastina, S. Poništ, F. Dráfi, K. Švík, S. Khademnematolahi, K. Pružinská, A. Tchorbanov, K. Bauerová","doi":"10.2478/afpuc-2022-0016","DOIUrl":null,"url":null,"abstract":"Abstract AIM The aim of this study was to explore the potential effect of natural compounds and their combination with methotrexate (M) on levels of matrix metalloproteinase-9 (MMP-9) as a key biochemical parameter in rat adjuvant arthritis. Further change of body weight was selected as one of clinical parameters monitored in this animal model. MATERIALS AND METHODS Adjuvant arthritis (AA) was induced in Lewis rats. Methotrexate (M) was administrated twice a week in a dose of 0.3 mg/kg b.w. The saffron extract was administrated daily in two doses: 25 mg/kg b.w. (SF1) and 50 mg/kg b.w. (SF2). Both doses were administrated alone and in combination with M. Astaxanthin was administrated also daily in two doses: 1 mg/kg b.w. (AS1) and 5 mg/kg b.w. (AS2) only as monotherapy. Carnosic acid was administrated daily in one dose: 100 mg/kg (C) in monotherapy and in combination with M. All compounds and M were administrated orally. Plasma samples were collected on the 21st experimental day and used for ELISA determination. The 21st experimental day was used also for the analysis of body weight changes. RESULTS We observed a significant decrease of MMP-9 plasmatic levels in SF1 and SF2 monotherapy in AA animal groups. The decrease in levels of MMP-9 in combined therapy of SF1 and M had higher significance than the effect of M only in AA. The same decreasing effect on the levels of MMP-9 was observed in the combined therapy of C and M. Astaxanthin and saffron extract had a very similar effect on clinical parameters and the change in body weight: both have significantly increased body weight in monotherapy in both doses used. The combined therapy of M and saffron extract doses showed no significant difference from M itself. Carnosic acid did not affect the change of body weight, and the combination of C with M reached the same level as M alone. CONCLUSION Astaxanthin in monotherapy and saffron extract in monotherapy and in combined therapy with M have significantly decreased plasmatic levels of MMP-9 and increased body weight in animals suffering from AA. Lower doses were more efficient for both experiments: astaxanthin and saffron extract. Carnosic acid has no effect in monotherapy in both parameters, but a combination with M has a significant effect with respect to the improvement of cachexia as well as the inhibition of inflammation.","PeriodicalId":12070,"journal":{"name":"European Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/afpuc-2022-0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract AIM The aim of this study was to explore the potential effect of natural compounds and their combination with methotrexate (M) on levels of matrix metalloproteinase-9 (MMP-9) as a key biochemical parameter in rat adjuvant arthritis. Further change of body weight was selected as one of clinical parameters monitored in this animal model. MATERIALS AND METHODS Adjuvant arthritis (AA) was induced in Lewis rats. Methotrexate (M) was administrated twice a week in a dose of 0.3 mg/kg b.w. The saffron extract was administrated daily in two doses: 25 mg/kg b.w. (SF1) and 50 mg/kg b.w. (SF2). Both doses were administrated alone and in combination with M. Astaxanthin was administrated also daily in two doses: 1 mg/kg b.w. (AS1) and 5 mg/kg b.w. (AS2) only as monotherapy. Carnosic acid was administrated daily in one dose: 100 mg/kg (C) in monotherapy and in combination with M. All compounds and M were administrated orally. Plasma samples were collected on the 21st experimental day and used for ELISA determination. The 21st experimental day was used also for the analysis of body weight changes. RESULTS We observed a significant decrease of MMP-9 plasmatic levels in SF1 and SF2 monotherapy in AA animal groups. The decrease in levels of MMP-9 in combined therapy of SF1 and M had higher significance than the effect of M only in AA. The same decreasing effect on the levels of MMP-9 was observed in the combined therapy of C and M. Astaxanthin and saffron extract had a very similar effect on clinical parameters and the change in body weight: both have significantly increased body weight in monotherapy in both doses used. The combined therapy of M and saffron extract doses showed no significant difference from M itself. Carnosic acid did not affect the change of body weight, and the combination of C with M reached the same level as M alone. CONCLUSION Astaxanthin in monotherapy and saffron extract in monotherapy and in combined therapy with M have significantly decreased plasmatic levels of MMP-9 and increased body weight in animals suffering from AA. Lower doses were more efficient for both experiments: astaxanthin and saffron extract. Carnosic acid has no effect in monotherapy in both parameters, but a combination with M has a significant effect with respect to the improvement of cachexia as well as the inhibition of inflammation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
藏红花提取物、虾青素和鼠尾草酸对关节炎患者基质金属蛋白酶-9水平及体重变化的影响
摘要目的探讨天然化合物及其联合甲氨蝶呤(M)对大鼠佐剂性关节炎关键生化指标基质金属蛋白酶-9 (MMP-9)水平的潜在影响。选择体重的进一步变化作为该动物模型监测的临床参数之一。材料与方法Lewis大鼠佐剂性关节炎(AA)。甲氨蝶呤(M)每周给药2次,剂量为0.3 mg/kg b.w。藏红花提取物每天给药2次:25 mg/kg b.w (SF1)和50 mg/kg b.w (SF2)。两种剂量均单独给药或与m联合给药,虾青素每日也以两种剂量给药:仅作为单药治疗,1 mg/kg b.w (AS1)和5 mg/kg b.w (AS2)。鼠尾草酸每日单剂量给药:100 mg/kg (C)单药和与M联合给药。实验第21天采集血浆标本,进行ELISA检测。试验第21天也进行体重变化分析。结果在AA动物组中,我们观察到SF1和SF2单药治疗组MMP-9血浆水平显著降低。SF1和M联合治疗对MMP-9水平的降低比M单独治疗对AA的影响具有更高的意义。在C和m的联合治疗中,观察到对MMP-9水平的相同降低效果。虾青素和藏红花提取物对临床参数和体重变化的影响非常相似:在使用的两种剂量的单药治疗中,两者都显着增加了体重。M与藏红花提取物剂量联合治疗与M本身无显著差异。鼠尾草酸对体重变化没有影响,C与M联合用药与M单独用药达到相同水平。结论虾青素单药治疗、藏红花提取物单药治疗及与M联合治疗均能显著降低AA动物血浆MMP-9水平,增加体重。低剂量的虾青素和藏红花提取物对两种实验都更有效。鼠尾草酸单药治疗在这两个参数上均无效果,但与M联合治疗在改善恶病质和抑制炎症方面均有显著效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Pharmaceutical Journal
European Pharmaceutical Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
0.60
自引率
0.00%
发文量
16
期刊介绍: European Pharmaceutical Journal publishes only original articles not previously published and articles that are not being considered or have not been submitted for publication elsewhere. If parts of the results have been published as conference abstract or elsewhere, it should be stated in references. The ethical standards of the Helsinki-Tokio Declaration should be kept. This should be mentioned in the Methods of manuscript. Reviews are published only on request. Authors, whose submitted research work was performed with the support of a company, should indicate this in Conflict of Interest.
期刊最新文献
Characterisation of the lipolytic enzymatic activities of fungal rizoenzymes from Rhizopus oryzae in comparison to pancreatin from pigs Physicochemical properties of tablet dosage form based on pre-gelatinized- and phosphorylated-modified starches from white-water yam (Dioscorea alata L.) Development and Characterisation of Valsartan Immediate Release Dosage Form Using Solubility Enhancement Technique Antimicrobial, Antifungal, Antioxidant Activity and Phytochemical Investigation of Phenolcarboxylic Acids by GC–MS of Raspberry (Rubus idaeus L.) Shoot Lipophilic Extract Formulation development, in-vitro and ex-vivo evaluation of dry adsorbed solid lipid nanoparticles: an approach of overcoming olanzapine drawbacks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1